Answers are grounded in this paper and cite their sources.
The influence of unilateral ocular instillation of B-HT 920 (50 micrograms) on regional ocular, cerebral and peripheral blood flows was investigated with the labelled microsphere method in conscious and anaesthetized albino rabbits. In urethane-anaesthetized rabbits the intraocular pressure (IOP) fell during 1 hr following topical B-HT 920 whereas no changes in regional blood flows were observed. Only in conscious rabbits was a decrease in regional blood flows found. B-HT 920 caused a short-term reduction in choroidal blood flow by about 20%. Transient vasoconstrictor effects, due to systemic absorption, were also seen in some extraocular tissues. Concomitantly, B-HT 920 reduced the total cerebral blood flow (CBF) by 23%. In the grey matter and hypothalamic region the decrease in flow was about 20%, while in the hippocampal region, thalamic region, collicles and pons-mesencephalon it was about 10%. In experiments with direct blood flow determination from an opened vortex vein, there was no consistent change of uveal vascular resistance, while IOP and mean arterial pressure (MAP) fell dose-dependently following cumulative intravenously administered bolus doses (10 and 50 micrograms/kg) of B-HT 920. Unilateral loss of the mediated sympathetic tone seemed to increase the ocular responses to B-HT 920, unmasking a vasoconstrictor effect. Additional systemic pretreatment with the selective blocking agents rauwolscine and sulpiride suggests that B-HT 920 produces its ocular hypotensive effect, predominantly by acting on dopamine (DA2) receptors in the eye rather than on alpha 2-adrenoceptors, and its ocular vasoconstrictor effects via both receptor types.
No takes yet. Share an insight, caveat, or question.
Thörig et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: